ACR in Review: Efficacy and cost of arthritis therapies are key
This article was originally published in Scrip
Executive Summary
There were no scene-stealing presentations of clinical trial data at the American College of Rheumatology (ACR) annual meeting this year, but concerns about the show-stopping costs of new pharmaceuticals was woven into studies and discussions of treatments for rheumatoid arthritis.